These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23086094)

  • 21. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.
    Verheugt FW; Granger CB
    Lancet; 2015 Jul; 386(9990):303-10. PubMed ID: 25777666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updated NICE guideline: management of atrial fibrillation (2014).
    Senoo K; Lau YC; Lip GY
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1037-40. PubMed ID: 25059099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel oral anticoagulants in cardiovascular disease.
    Gallego P; Roldán V; Lip GY
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):34-44. PubMed ID: 24038020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transitions of care in anticoagulation management for patients with atrial fibrillation.
    Deitelzweig SB
    Hosp Pract (1995); 2012 Oct; 40(4):20-7. PubMed ID: 23299032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Why NAO: Know How. Why and how to choose the new oral anticoagulant in cardiological clinical practice].
    Rossini R; Pecora D; Ferlini M; Gentile F; Moschini L; Pedrinazzi C; Ravizza P; Romano M; Canova P; Oliva F
    G Ital Cardiol (Rome); 2015 Mar; 16(3):161-74. PubMed ID: 25837460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation.
    Fernandez MM; von Schéele B; Hogue S; Kwong WJ
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):87-102. PubMed ID: 23572283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
    Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated guidelines on outpatient anticoagulation.
    Wigle P; Hein B; Bloomfield HE; Tubb M; Doherty M
    Am Fam Physician; 2013 Apr; 87(8):556-66. PubMed ID: 23668445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S; Giansante C
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [ANMCO statement on prevention of thromboembolism in atrial fibrillation and role of the new oral anticoagulants].
    Colonna P; Abrignani MG; Colivicchi F; Verdecchia P; Alunni G; Bongo AS; Ceravolo R; Oliva F; Rakar S; Riccio C; Scherillo M; Valle R; Bovenzi F;
    G Ital Cardiol (Rome); 2013 Apr; 14(4):295-322. PubMed ID: 23567775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New versus traditional approaches to oral anticoagulation in patients with atrial fibrillation.
    Reiffel JA
    Am J Med; 2014 Apr; 127(4):e15. PubMed ID: 24655741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel oral anticoagulants in atrial fibrillation: which novel oral anticoagulant for which patient?
    Prisco D; Cenci C; Silvestri E; Ciucciarelli L; Di Minno G
    J Cardiovasc Med (Hagerstown); 2015 Jul; 16(7):512-9. PubMed ID: 25798903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.